CST, 97411S, TAF-I alpha (F3E2E) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying SET. Validated for Western Blotting,Simple Western™,Immunoprecipitation. Available in 2 sizes. Highly specific and rigorously validated in-house, TAF-I alpha (F3E2E) Rabbit Monoclonal Antibody (CST #97411) is ready to ship. Product Usage Information Western Blotting: 1:1000 Simple Western™: 1:10 - 1:50 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity TAF-I alpha (F3E2E) Rabbit Monoclonal Antibody recognizes endogenous levels of total TAF-Iα protein. This antibody does not cross-react with TAF-Iβ protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro8 of human TAF-Iα protein. Background Templated activating factor I (TAF-I), also known as SET, is a histone chaperone protein first discovered to play a role in adenovirus chromatin replication (1,2). TAF-I is an acidic protein capable of binding histone cores and remodeling nucleosomes (3). TAF-I is part of the inhibitor of acetyltransferases (INHAT) complex, which sharply represses histone acetylation by PCAF and P300/CBP (4). INHAT complex binding to histone tails is affected by certain histone marks (5). TAF-I has two predominant isoforms, TAF-Iα and TAF-Iβ, which only differ in the N-terminus. TAF-Iα is the predominant isoform in embryonic stem cells, and its expression is regulated by pluripotent factors. Upon differentiation, an isoform shift takes place as the alternative promoter is upregulated, generating TAF-Iβ (6-8). TAF-I uniquely exhibits histone chaperone activity toward linker histone H1, regulating higher-order chromatin structure. TAF-Iα has less activity than TAF-Iβ due to its inhibitory interaction between its unique N-terminus and the C-terminus (9,10). TAF-I has been implicated in oncogenic transformation by inhibiting apoptosis (11). Alternate Names 2PP2A; chromatin remodelling factor; HLA-DR-associated protein II; I-2PP2A; I2PP2A; IGAAD; Inhibitor of granzyme A-activated DNase; inhibitor-2 of protein phosphatase-2A; IPP2A2; MRD58; PHAPII; Phosphatase 2A inhibitor I2PP2A; protein phosphatase type 2A inhibitor; Protein SET; SET; SET nuclear oncogene; SET nuclear proto-oncogene; SET translocation (myeloid leukemia-associated); TAF-I; TAF-IBETA; Template-activating factor I; Template-Activating Factor-I, chromatin remodelling factor Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 45 Source/Isotype: Rabbit IgG